<DOC>
	<DOCNO>NCT00527410</DOCNO>
	<brief_summary>This study assess tolerability , safety , efficacy pharmacokinetics RTA 744 recurrent neoplastic meningitis .</brief_summary>
	<brief_title>A Safety Study RTA 744 Recurrent , Progressive Refractory Neoplastic Meningitis</brief_title>
	<detailed_description>Neoplastic meningitis refers deposition malignant cell line ( leptomeninges ) brain spine . Neoplastic meningitis solid tumor often occur patient advanced systemic disease fail prior chemotherapy ; also frequent patient CNS parenchymal metastasis . Patient survival remain low , good treatment need penetrate blood brain barrier treat entire neuraxis . RTA 744 close chemical analogue well characterize anti-cancer agent doxorubicin . Unlike doxorubicin , RTA 744 show ability cross blood brain barrier achieve high concentration CNS tumor tissue animal model . Dose escalation continue pre-determined first occurrence dose-limiting toxicity . Maximum tolerate dose determine define protocol .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<criteria>Histologic confirmation primary malignancy . All primary tumor type may enrol . Neoplastic meningitis/leptomeningeal metastasis refractory conventional therapy presence tumor cell cytology , OR neuroimaging evidence leptomeningeal tumor MRI . Not eligible high priority clinical trial . Have recover side effect surgical resection . A stable dose steroid least 7 day prior GdMRI . Karnofsky Performance Status ( KPS ) ≥ 60 . Laboratory Parameters : ANC ≥ 1.5 x 109/L ; Hgb ≥ 9 g/dl ; Platelets ≥ 100 x 109/L ; AST ALT ≤ 3.0 x ULN ; Serum bilirubin ≤ 1.5 x ULN ; Serum creatinine ≤ 1.5 x ULN ; 24 hour creatinine clearance ≥ 50 ml/min Life expectancy least 8 week . Written inform consent obtain . Concurrent therapy leptomeningeal disease malignancy . Clinical evidence obstructive hydrocephalus compartmentalization CSF flow . Cumulative dos : doxorubicin &gt; 450 550 mg/m2 , epirubicin &gt; 8001000 mg/m2 , idarubicin &gt; 130150 mg/m2 daunorubicin &gt; 400550 mg/m2 . Anticonvulsant medication type medication know induce CYP450 enzyme . Pregnancy breast feeding , adult ( male female ) reproductive potential employ effective method birth control Total 24 hour urinary protein &gt; 500 mg. Concurrent severe and/or uncontrolled medical condition could compromise participation study Impaired cardiac function , significant prior cardiac disease arrhythmia type Myocardial infarction ≤ 6 month prior History CHF arrhythmias Therapeutic dos anticoagulant therapy ( prophylactic dosing allow ) Investigational drug less 4 week prior ; intrathecal chemotherapy within 2 week prior ; systemic cytotoxic chemotherapy within 4 week prior ( 6 week nitrosourea mitomycinC 2 week vincristine ) ; radiation therapy within 2 week prior ; medication know cause QT interval prolongation Any surgery &lt; 2 week prior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>